Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists
Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists New research from Spherix Global Insights finds the impressive uptake of AbbVies Ubrelvy and Biohavens Nurtec ODT appears to have already blunted reliance on the subcutaneous CGRP monoclonal antibodies, with growth of Amgen/Novartis Aimovig, Tevas Ajovy, and Eli Lillys Emgality all moderating News provided by Share this article Share th...
Amgen Novarti Aimovig Abbvie Ubrelvy Eli Lilly Emgality Teva Ajovy Look Next Transform Preventive Treatment
Source: prnewswire.com